Otsuka Novel Products GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.otsuka-onpg.com
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Phase 1
Terminated
- Conditions
- Breast CancerOvarian CancerProstate CancerSalivary Gland CancerEndometrial CancerSquamous Cell Carcinoma of the Cervix
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Otsuka Novel Products GmbH
- Target Recruit Count
- 79
- Registration Number
- NCT02042885
- Locations
- 🇬🇧
NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital, London, United Kingdom
🇬🇧The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, Sutton, Surrey, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath